Elevation Oncology

GSK's Blenrep Secures UK Approval for Multiple Myeloma Treatment in Combination Therapy

2 months ago

• The UK's medicines regulatory body has approved GSK's Blenrep (belantamab mafodotin) in combination with other drugs for multiple myeloma patients whose first treatment failed or caused severe side effects. • This approval marks a significant comeback for Blenrep, which was withdrawn from markets in 2022 after failing to outperform existing treatments when used as monotherapy. • Clinical trials demonstrated Blenrep's combination therapy extended progression-free survival and overall survival compared to standard care regimens, including those based on Darzalex (daratumumab).

Elevation Oncology Advances ADC Programs Targeting Gastric and GEJ Cancers

4 months ago

• Elevation Oncology initiated dosing of EO-3021, a Claudin 18.2 ADC, in combination with ramucirumab or dostarlimab for advanced gastric/GEJ cancer patients. • Additional monotherapy data from the Phase 1 trial of EO-3021 is expected in the first half of 2025, building on promising initial results. • Preclinical data for EO-1022, a HER3 ADC, will be presented in the first half of 2025, with plans to file an IND application in 2026. • Initial data from the combination cohorts of EO-3021 are anticipated in late 2025 or early 2026, evaluating synergistic benefits.

Focused Ultrasound Shows Promise in Alzheimer's Treatment

4 months ago

• A clinical trial using focused ultrasound to treat Alzheimer’s disease has shown promising results, marking a potential new direction in treating this debilitating condition. • The study, published in the Journal of Neurosurgery, highlights the noninvasive nature of focused ultrasound as a key advantage in Alzheimer's treatment. • Researchers are optimistic about the potential of this approach to offer a new therapeutic avenue for patients suffering from Alzheimer's disease. • Further research is needed to fully understand the long-term effects and optimal use of focused ultrasound in Alzheimer's treatment.

Biopharma Industry Faces Continued Layoffs in 2025 Amid Strategic Realignments

5 months ago

• Biopharma companies continue to announce layoffs in 2025, driven by strategic realignments, pipeline reprioritizations, and challenging financial conditions. • Several companies, including Intellia Therapeutics and IGM Biosciences, are cutting a significant portion of their workforce to focus on key programs and extend cash runways. • These workforce reductions are often accompanied by discontinuation of certain drug development programs and a shift in strategic focus towards core assets. • The layoffs reflect a broader trend in the industry as companies adapt to evolving market dynamics and prioritize efficiency and long-term sustainability.

Esophageal Cancer Treatment Landscape Evolves with Novel Therapies and Approvals

5 months ago

• The esophageal cancer market is expected to grow significantly, driven by increasing prevalence and the introduction of novel therapies. • In 2023, approximately 77,000 new cases of esophageal cancer were reported across seven major markets, with Japan having the highest number. • Recent FDA approval of TEVIMBRA (tislelizumab) as a monotherapy marks a significant advancement in treating unresectable or metastatic ESCC. • Emerging therapies like zanidatamab and bemarituzumab are expected to revolutionize the esophageal cancer market dynamics during the forecast period.

Elevation Oncology: Promising Cancer Therapies Earn Analyst Praise

5 months ago

William Blair analyst Andy Hsieh praises Elevation Oncology for its promising cancer therapies, particularly its antibody-drug conjugate expertise targeting Claudin 18.2 and HER3, highlighting a favorable risk-to-reward ratio and significant market potential.

Oncolytics Biotech and Bio-Path Holdings Announce Promising Cancer Therapy Advancements

6 months ago

• Oncolytics Biotech presented data at the ASCO GI Symposium, highlighting pelareorep's potential in treating relapsed anal and metastatic pancreatic cancers. • A GOBLET study cohort showed a 33% objective response rate in relapsed anal cancer patients treated with pelareorep and atezolizumab, including a complete response lasting over 15 months. • Bio-Path Holdings reported a meaningful patient response in a Phase 1/1b trial of BP1002 for refractory/relapsed AML, with stable disease and reduced blast count after one treatment cycle. • Bio-Path Holdings' BP1001-A demonstrated continued tumor reduction and stable disease in a solid tumor patient, alongside durable remissions in AML patients treated with prexigebersen.

Elevation Oncology's EO-3021 Shows Promise in Gastric and GEJ Cancers

7 months ago

• Elevation Oncology's EO-3021 demonstrated a 42.8% confirmed objective response rate (ORR) in Claudin 18.2-enriched gastric and GEJ cancer patients. • The Phase 1 trial of EO-3021 has progressed into the dose expansion phase, with additional monotherapy data expected in the first half of 2025. • Combination trials of EO-3021 with VEGFR2 and PD-1 inhibitors are set to begin in Q4 2024, with preclinical data presented at ESMO-IO 2024. • The FDA granted Fast Track designation to EO-3021 for advanced or metastatic gastric and GEJ cancers expressing Claudin 18.2 after prior therapy.

Elevation Oncology's EO-3021 Shows Promise in Gastric and GEJ Cancer Treatment

7 months ago

• Elevation Oncology's EO-3021 demonstrated a 42.8% confirmed objective response rate (ORR) in Claudin 18.2-enriched gastric and GEJ cancer patients in Phase 1 trials. • Preclinical data presented at ESMO-IO 2024 supports the combination potential of EO-3021 with VEGFR2 or PD-1 inhibitors, showing synergistic anti-tumor activity. • The FDA granted Fast Track designation to EO-3021 for advanced or metastatic gastric and GEJ cancer expressing Claudin 18.2, expediting its development. • Elevation Oncology plans to initiate dosing in the combination portion of the Phase 1 trial of EO-3021 in Q4 2024, with additional monotherapy data expected in 1H 2025.

FDA Grants Fast Track Designation to Elevation Oncology's EO-3021 for Gastric and GEJ Cancers

8 months ago

• The FDA has granted Fast Track designation to EO-3021 for advanced or metastatic gastric and gastroesophageal junction (GEJ) cancer expressing Claudin 18.2. • EO-3021, a differentiated antibody-drug conjugate, targets Claudin 18.2, a protein exposed in malignant transformation of gastric epithelial cells. • The Fast Track designation aims to expedite the development and review of EO-3021, offering potential for priority review and accelerated approval. • Early Phase 1 trial results showed a 42.8% overall response rate in a Claudin 18.2-enriched subset of gastric and GEJ cancer patients.

FDA Approves Astellas' Vyloy (Zolbetuximab) for Advanced Gastric and GEJ Adenocarcinoma

8 months ago

• The FDA has approved zolbetuximab (Vyloy) in combination with chemotherapy for first-line treatment of CLDN18.2-positive, HER2-negative gastric or GEJ adenocarcinoma. • Approval was based on SPOTLIGHT and GLOW trials, demonstrating statistically significant improvements in progression-free and overall survival compared to chemotherapy alone. • The VENTANA CLDN18 (43-14A) RxDx Assay from Roche was also approved as a companion diagnostic to identify patients eligible for Vyloy treatment. • Vyloy is now approved in five markets worldwide, offering a new targeted therapy option for a subset of gastric and GEJ cancer patients.

Elevation Oncology's EO-3021 Shows Promise in Claudin 18.2-Expressing Solid Tumors

10 months ago

• EO-3021 demonstrates a 42.8% objective response rate in gastric and GEJ cancer patients with high Claudin 18.2 expression. • The antibody-drug conjugate exhibits a favorable safety profile, with minimal MMAE-associated toxicities, including no neutropenia or peripheral neuropathy. • Elevation Oncology plans to advance EO-3021 into the dose expansion phase of the Phase 1 trial and initiate combination studies. • Additional monotherapy data from the Phase 1 trial is expected in the first half of 2025, with combination dosing to begin by year-end 2024.